NURO is a low float buyout target. NURO’s current mkt cap is $3m with giant Pharma Glaxosmithkline as a partner and responsible for $5.5m in payments to Nuro. “Through June 30, 2019, GSK has paid the Company $19.5 million in milestone payments. GSK has committed to future performance milestone payments totaling up to $5.5 million...